Atnaujinkite slapukų nuostatas

Pediatric Psychodermatology: A Clinical Manual of Child and Adolescent Psychocutaneous Disorders [Kietas viršelis]

Edited by , Edited by , Contributions by , Contributions by , Edited by , Edited by , Contributions by , Preface by , Edited by , Preface by
  • Formatas: Hardback, 596 pages, aukštis x plotis: 240x170 mm, weight: 1219 g, 100 Tables, black and white; 60 Illustrations, color; 60 Illustrations, black and white
  • Serija: Health, Medicine and Human Development
  • Išleidimo metai: 15-Nov-2012
  • Leidėjas: De Gruyter
  • ISBN-10: 311027387X
  • ISBN-13: 9783110273878
Kitos knygos pagal šią temą:
Pediatric Psychodermatology: A Clinical Manual of Child and Adolescent Psychocutaneous DisordersDidesnis paveikslėlis
  • Formatas: Hardback, 596 pages, aukštis x plotis: 240x170 mm, weight: 1219 g, 100 Tables, black and white; 60 Illustrations, color; 60 Illustrations, black and white
  • Serija: Health, Medicine and Human Development
  • Išleidimo metai: 15-Nov-2012
  • Leidėjas: De Gruyter
  • ISBN-10: 311027387X
  • ISBN-13: 9783110273878
Kitos knygos pagal šią temą:
Pastovi nuoroda: https://www.kriso.lt/db/9783110273878.html
Psychodermatologic disorders comprise for up to one third of dermatologic conditions in different clinical settings. By virtue of their complex nature these disorders can be very difficult to treat and adversely impact long term outcomes. This book examines the bidirectional relationship between psychiatry and dermatology in children and adolescents. The information are presented in an easy to follow format to be used as a clinical reference by physicians and paramedical staff in various fields of medicine including pediatrics, primary care, internal medicine, psychiatry and dermatology.

"Ruqiya Shama Tareen, Donald E. Greydanus, Mohammad Jafferany, and Dilip R. Patel, Michigan State University, East Lansing, Michigan, USA; Joav Merrick, Ministry of Social Affairs and Social Services, Jerusalem, Israel. "
Foreword I xxiii
Foreword II xxvii
Preface xxix
Author index xxxvii
Abbreviations xli
Part I INTERFACE OF DERMATOLOGY AND PSYCHIATRY
1(116)
1 Perspectives on management of pediatric dermatologic disorders
3(66)
Arthur N. Feinberg
Tor A. Shwayder
Ruqiya Shama Tareen
Therdpong Tempark
1.1 Introduction
3(1)
1.2 Skin infections and infestations
3(16)
1.2.1 Bacterial infections
3(12)
1.2.2 Viral infections
15(4)
1.3 HIV/AIDS
19(10)
1.3.1 Non-infectious skin lesions
19(1)
1.3.2 Bacterial infections in HIV
19(1)
1.3.3 Viral infections in HIV
20(1)
1.3.4 Fungal infections in HIV
20(1)
1.3.5 Fungal infections
21(4)
1.3.6 Topical antifungals
25(1)
1.3.7 Infestations
26(3)
1.4 Dermatitis
29(4)
1.4.1 Irritant dermatitis
29(1)
1.4.2 Dry-skin dermatitis
29(1)
1.4.3 Seborrheic dermatitis
29(1)
1.4.4 Allergic dermatitides
30(3)
1.4.5 Idiopathic dermatitides
33(1)
1.5 Hypersensitivity
33(4)
1.5.1 Urticaria
33(2)
1.5.2 Drug eruptions
35(2)
1.6 Miscellaneous skin conditions
37(15)
1.6.1 Acne vulgaris
37(4)
1.6.2 Nevi
41(3)
1.6.3 Papulosquamous disorders
44(2)
1.6.4 Lichens
46(3)
1.6.5 Psoriasis
49(3)
1.7 Dermatologie manifestations of systematic disorders
52(2)
1.7.1 Pruritus without rash
52(1)
1.7.2 Inflammatory bowel disease (IBD)
53(1)
1.7.3 Erythema nodosum
53(1)
1.7.4 Pyoderma gangrenosum
53(1)
1.7.5 Less common skin manifestations
53(1)
1.7.6 Management
53(1)
1.8 Collagen vascular disease
54(1)
1.8.1 Lupus erythematosus (SLE)
54(1)
1.8.2 Dermatomyositis
54(1)
1.8.3 Juvenile idiopathic arthritis
54(1)
1.8.4 Management
54(1)
1.9 Endocrinologic disorders
55(1)
1.9.1 Thyroid disorders
55(1)
1.9.2 Diabetes mellitus
55(1)
1.9.3 Adrenal disorders
55(1)
1.9.4 Management
56(1)
1.10 Hair and nails
56(13)
1.10.1 Alopecia areata
56(2)
1.10.2 Telogen effluvium
58(1)
1.10.3 Androgenic alopecia
58(1)
1.10.4 Trichotillomania
59(1)
1.10.5 Traction alopecia
59(1)
1.10.6 Hirsutism and hypertrichosis
59(1)
1.10.7 Hair changes with systemic disease
60(1)
1.10.8 Infection
60(2)
1.10.9 Bacterial
62(1)
1.10.10 Fungal
63(1)
1.10.11 Onychodystrophy
64(1)
1.10.12 Nail changes with systemic and nutritional disorders
65(4)
2 Psychoneuroimmunology and other interactions between skin and psyche
69(14)
Ruqiya Shama Tareen
2.1 Introduction
69(6)
2.1.1 History of psychodermatology
70(2)
2.1.2 Classification of psychodermatologic disorders
72(1)
2.1.3 Psychological perspective of skin
72(2)
2.1.4 Skin, mind, and the embryological embrace
74(1)
2.2 Psychoneuroimmunology
75(5)
2.2.1 Neuroendocrine response to stress
75(1)
2.2.2 Immune response and central nervous system
76(1)
2.2.3 Immune response and peripheral nervous system
77(1)
2.2.4 Immune response and skin disease
77(2)
2.2.5 Immune response and psychiatric disease
79(1)
2.3 Conclusion
80(3)
3 A clinicians approach to psychocutaneous diseases in adolescents: Untying the Gordian knot
83(12)
Donald E. Greydanus
3.1 Introduction
83(2)
3.1.1 History taking skills in adolescent patients
83(2)
3.2 Interviewing the adolescent patient
85(5)
3.2.1 Confidentiality
87(1)
3.2.2 Parental confidentiality
87(1)
3.2.3 Health questionnaires
87(1)
3.2.4 Interview techniques
88(1)
3.2.5 Active listening skills
89(1)
3.3 Concepts of the physical examination
90(1)
3.4 Successful management of the adolescent patient
90(2)
3.4.1 Informed consent
90(1)
3.4.2 Shared decision making
91(1)
3.4.3 Improving compliance
92(1)
3.5 Conclusion
92(3)
4 Quality of life issues in children and adolescents with dermatological conditions and their wider impact on the family and society
95(22)
Mohammad Khurshid
Azam Basra
4.1 Introduction
95(1)
4.2 Pediatric quality of life and its assessment
96(1)
4.3 Skin disease and quality of life
97(5)
4.3.1 Impact of skin diseases on childrens quality of life
97(2)
4.3.2 Quality of life assessment in children with dermatological conditions
99(1)
4.3.3 Childrens Dermatology Life Quality Index (CDLQI)
100(1)
4.3.4 Infants Dermatitis Quality of Life Index (IDQoL)
100(1)
4.3.5 Impact of skin disease on the quality of life of adolescents
101(1)
4.4 Assessment of adolescents quality of life in dermatology
102(4)
4.4.1 Teenagers QoL questionnaire CT-QoL)
102(1)
4.4.2 Skindex-Teen
103(1)
4.4.3 Impact of skin disease on family quality of life: The "greater patient" concept
104(2)
4.5 Assessment of family quality in dermatology
106(3)
4.5.1 Family Dermatology Life Quality Index (FDLQI)
106(1)
4.5.2 Dermatitis Family Impact questionnaire (DFI)
107(1)
4.5.3 Parents Index of Quality of Life in Atopic Dermatitis (PIQoL-AD)
108(1)
4.5.4 Childhood Atopic Dermatitis Impact Scale (CADIS)
108(1)
4.5.5 Psoriasis Family Index (PFI)
109(1)
4.6 Societal impact of childhood dermatological conditions
109(1)
4.7 Conclusions
110(7)
Part II PSYCHOPHYSIOLOGIC DISORDERS
117(82)
5 Atopic dermatitis: a psychocutaneous review
119(28)
Ruqiya Shama Tareen
5.1 Introduction
119(1)
5.1.1 Epidemiology
119(1)
5.2 Pathophysiologic factors in atopic dermatitis
120(1)
5.2.1 Genetic predisposition
120(1)
5.2.2 Socio-economic status
120(1)
5.2.3 Family size
120(1)
5.2.4 Food allergens
120(1)
5.3 Psychoneuroimmunologic factors
121(1)
5.3.1 Breast feeding
121(1)
5.3.2 Environmental allergens
121(1)
5.4 Psychophysiological aspects of atopic dermatitis
122(3)
5.4.1 Impact of stress on the immunological system
122(1)
5.4.2 Psychoanalytic hypothesis
123(1)
5.4.3 Biopsychosocial model
124(1)
5.4.4 Psychological dysregulation due to atopic dermatitis
124(1)
5.5 Clinical features
125(1)
5.6 Diagnosis
125(3)
5.6.1 Allergy Testing
127(1)
5.6.2 Differential Diagnosis
128(1)
5.7 Management
128(6)
5.7.1 Prevention of relapse
128(1)
5.7.2 Food allergens
129(1)
5.7.3 Aeroallergens
129(1)
5.7.4 Optimizing the epidermal barrier (EB)
129(1)
5.7.5 Hydration therapy
130(1)
5.7.6 Management of pruritus
130(1)
5.7.7 Topical corticosteroids
131(3)
5.7.8 Topical immunomodulators
134(1)
5.8 Systematic treatment of atopic dermatits
134(4)
5.8.1 Antihistamines
134(1)
5.8.2 Phototherapy
135(1)
5.8.3 Antibiotics
135(1)
5.8.4 Systemic corticosteroids
136(1)
5.8.5 Immunomodulators
136(1)
5.8.6 Cyclosporine
137(1)
5.8.7 Azathioprine
137(1)
5.8.8 Infliximab
137(1)
5.8.9 Interferon-y
138(1)
5.8.10 Leukotriene inhibitors
138(1)
5.9 Psychiatric comorbidities
138(3)
5.9.1 Family dynamics
139(1)
5.9.2 Internalizing and externalizing behaviors
139(1)
5.9.3 Anxiety and depression
140(1)
5.9.4 Personality traits
140(1)
5.10 Management of psychiatric comorbidities
141(3)
5.10.1 Multidisciplinary approach
141(1)
5.10.2 Psychoeducation
141(1)
5.10.3 Psychosocial assessment
141(1)
5.10.4 Psychiatric symptoms review
142(1)
5.10.5 Quality of life assessment
142(1)
5.10.6 Psychodynamic therapy
142(1)
5.10.7 Cognitive behavioral therapy
143(1)
5.10.8 Behavioral modifications
143(1)
5.10.9 Psychotropic medications
143(1)
5.11 Conclusion
144(3)
6 Psoriasis and children: A psychological approach
147(16)
Sandra Ros
Eulalia Baselga
6.1 Introduction
147(1)
6.1.1 Epidemiology
148(1)
6.2 Dermatological clinical features
148(4)
6.2.1 Plaque psoriasis
149(1)
6.2.2 Guttate psoriasis
149(1)
6.2.3 Erythrodermic psoriasis
149(1)
6.2.4 Pustular psoriasis
150(1)
6.2.5 Psoriatic arthritis
151(1)
6.2.6 Inverse psoriasis
151(1)
6.3 Psychological clinical features
152(7)
6.3.1 Differential diagnosis
154(1)
6.3.2 Psychotherapeutic intervention
155(1)
6.3.3 Psychotherapy
156(3)
6.4 Conclusions
159(4)
7 The acnes: Acne vulgaris, acne rosacea, and acne excoriee
163(30)
Donald E. Greydanus
7.1 Acne Vulgaris
163(21)
7.1.1 Introduction
163(1)
7.1.2 Epidemiology
163(4)
7.1.3 Pathogenesis
167(1)
7.1.4 Classification
168(1)
7.1.5 Management
168(11)
7.1.6 Teratogenicity and Isotretinoin
179(1)
7.1.7 Depression, suicidality, and isotretinoin
180(4)
7.2 Acne Rosacea
184(3)
7.2.1 Pathophysiology
185(1)
7.2.2 Management of acne rosacea
186(1)
7.3 Acne Variants
187(1)
7.4 Conclusion
187(6)
8 Psychogenic purpura (Gardner-Diamond syndrome)
193(6)
Mohammad Jafferany
8.1 Introduction
193(1)
8.2 History
193(1)
8.3 Etiology and pathogenesis
194(1)
8.4 Clinical features
195(1)
8.5 Differential diagnosis
195(1)
8.5.1 Disease course
195(1)
8.5.2 Histopathology
195(1)
8.5.3 Laboratory testing
196(1)
8.5.4 Psychological disturbances
196(1)
8.6 Treatment approaches and recommendations
196(1)
8.7 Conclusion
197(2)
Part III PSYCHIATRIC DISORDERS WITH DERMATOLOGIC MANIFESTATIONS
199(82)
9 Body dysmorphic disorder in adolescents
201(16)
Lucia Tomas-Aragones
Servando E. Marron
9.1 Introduction
201(1)
9.2 Definition
202(3)
9.2.1 Epidemiology
203(1)
9.2.2 Clinical features
203(1)
9.2.3 Differential diagnosis
204(1)
9.3 Management
205(5)
9.3.1 Preliminary considerations
205(1)
9.3.2 The clinical Interview
206(1)
9.3.3 Assessment
206(2)
9.3.4 Patient education
208(1)
9.3.5 Treatment
208(2)
9.4 Other treatment techniques
210(3)
9.4.1 Anxiety management training (AMT)
210(1)
9.4.2 Eye movement desensitization and reprocessing (EMDR)
211(1)
9.4.3 Family therapy
211(1)
9.4.4 Group therapy
211(1)
9.4.5 Metaphors
211(1)
9.4.6 Mindfulness
212(1)
9.4.7 Intervention
212(1)
9.4.8 Nonpsychiatric medical treatment
212(1)
9.4.9 Final management considerations
213(1)
9.5 Conclusions
213(4)
10 Delusional infestation in childhood, adolescence, and adulthood
217(20)
Peter Lepping
Roland W. Freudenmann
10.1 Introduction
217(1)
10.2 How to diagnose a delusion
218(1)
10.3 Primary and secondary delusional infestation
219(1)
10.4 The context of children and adolescence
220(1)
10.5 Clinical pictures
221(3)
10.5.1 Case one
221(1)
10.5.2 Case two
222(1)
10.5.3 Case Three
223(1)
10.5.4 Commentary on these three cases
224(1)
10.6 Delusional elaboration ("Wahnarbeit")
224(2)
10.7 Prevalence of delusional infestation
226(4)
10.7.1 Treatment
227(1)
10.7.2 Which antipsychotic in DI?
228(2)
10.8 Antipsychotics
230(2)
10.9 Conclusion
232(5)
11 Dermatitis artefacta, skin picking, and other self-injurious behaviors: A psychological perspective
237(24)
Helen D. Pratt
11.1 Introduction
237(2)
11.2 Epidemiology
239(2)
11.3 Etiology
241(2)
11.4 Clinical features
243(5)
11.4.1 Dermatitis Artefacta
245(1)
11.4.2 Skin picking
246(1)
11.4.3 Self-mutilation behavior
246(2)
11.5 Differential diagnosis
248(1)
11.6 Management
248(9)
11.6.1 Pharmacological Treatment
251(1)
11.6.2 Psychotherapy
251(4)
11.6.3 Issues with Treatment
255(2)
11.7 Conclusions
257(4)
12 Trichotillomania
261(10)
Arthur N. Feinberg
12.1 Introduction
261(1)
12.2 Definition
261(1)
12.3 Differential diagnosis
262(2)
12.4 Assessment
264(2)
12.5 Management
266(2)
12.5.1 Psychotherapy
267(1)
12.5.2 Medication
267(1)
12.6 Conclusions: Future directions
268(3)
13 Psychogenic pruritus with particular emphasis on children and adolescents
271(10)
Adam Reich
Jacek C. Szepietowski
13.1 Introduction
271(1)
13.2 Epidemiology
272(1)
13.3 Clinical features
273(1)
13.4 Differential diagnosis
274(1)
13.5 Management
275(2)
13.6 Conclusion
277(4)
Part IV DERMATOLOGIC DISORDERS PREDISPOSING TO PSYCHIATRIC DISORDERS
281(40)
14 Disorders of hair loss
283(12)
Dilip R. Patel
14.1 Introduction
283(1)
14.2 Causes of hair loss
283(2)
14.3 Diagnostic approach to hair loss
285(1)
14.3.1 History
285(1)
14.3.2 Examination
285(1)
14.3.3 Laboratory investigation
286(1)
14.4 Tinea capitis
286(1)
14.5 Telogen effluvium
287(1)
14.6 Alopecia areata
287(1)
14.7 Male pattern hair loss
288(1)
14.8 Hair Loss due to Chemotherapy
288(1)
14.9 Psychiatric aspects
288(3)
14.9.1 Psychological treatment approaches
290(1)
14.10 Conclusion
291(4)
15 Disorders of skin pigmentation
295(12)
Dilip R. Patel
15.1 Introduction
295(1)
15.2 Disorders of hypopigmentation
296(4)
15.2.1 Vitiligo
296(2)
15.2.2 Albinism
298(1)
15.2.3 Postinflammatory hypopigmentation
298(1)
15.2.4 Pityriasis alba
299(1)
15.2.5 Tinea versicolor
299(1)
15.3 Disorders of hyperpigmentation
300(1)
15.3.1 Postinflammatory hyperpigmentation
300(1)
15.3.2 Melasma
300(1)
15.3.3 Hyperpigmentation associated with medical disorders
300(1)
15.3.4 Cafe-au-lait spots
301(1)
15.3.5 Lentigines
301(1)
15.4 Psychological aspects of disorders of pigmentations
301(3)
15.4.1 Psychosocial management of disorders of pigmentation
303(1)
15.5 Conclusion
304(3)
16 Skin adnexal disorders
307(14)
Ladan Mostaghimi
16.1 Hidradenitis suppurativa (HS)
307(4)
16.1.1 Introduction
307(1)
16.1.2 Diagnosis
307(1)
16.1.3 Etiology
308(1)
16.1.4 Clinical features
309(1)
16.1.5 Differential Diagnosis
310(1)
16.2 Hyperhidrosis
311(5)
16.2.1 Definition
311(1)
16.2.2 Epidemiology
312(1)
16.2.3 Etiology
312(1)
16.2.4 Clinical features
313(1)
16.2.5 Differential diagnosis
313(1)
16.2.6 Management
314(2)
16.3 Anhidrotic ectodermal dysplasia
316(1)
16.3.1 Definition
316(1)
16.3.2 Epidemiology
316(1)
16.3.3 Clinical features
316(1)
16.3.4 Differential diagnosis
316(1)
16.3.5 Management
317(1)
16.4 Nevus sebaceous
317(1)
16.4.1 Definition
317(1)
16.4.2 Epidemiology
317(1)
16.4.3 Clinical features
317(1)
16.4.4 Differential diagnosis
318(1)
16.4.5 Management
318(1)
16.5 Conclusion
318(3)
Part V SYSTEMATIC DISEASES WITH PSYCHODERMATOLOGIC MANIFESTATIONS
321(100)
17 Neurocutaneous disorders
323(12)
Zeba Hasan Hafeez
17.1 Introduction
323(1)
17.2 Neurofibromatosis
323(5)
17.2.1 Clinical features
325(1)
17.2.2 Neuropsychiatric aspects of neurofibromatosis type 1
325(1)
17.2.3 Management
326(2)
17.2.4 NF1 summary
328(1)
17.3 Tuberous Sclerosis Complex (TSC)
328(4)
17.3.1 Introduction
328(1)
17.3.2 Clinical features of TSC
329(1)
17.3.3 Neurologic lesions
329(1)
17.3.4 Psychiatric symptoms
329(1)
17.3.5 Management
330(1)
17.3.6 Treatment of neuropsychiatrie problems
330(2)
17.4 Conclusion
332(3)
18 Collagen vascular disorders: Psychiatric and dermatologic manifestations
335(26)
Manmohan K. Kamboj
Ruqiya Shama Tareen
18.1 Lupus erythematosus (LE)
335(9)
18.1.1 Epidemiology
335(1)
18.1.2 Clinical features
335(1)
18.1.3 Cutaneous manifestations
336(1)
18.1.4 Neuropsychiatric systemic lupus erythematosus (NPSLE)
337(3)
18.1.5 Differential diagnosis
340(1)
18.1.6 Clinical diagnosis
340(2)
18.1.7 Diagnostic workup
342(1)
18.1.8 Management
342(1)
18.1.9 Treatment of cutaneous lupus lesions
343(1)
18.1.10 Treatment of NPSLE
343(1)
18.2 Dermatomyositis
344(4)
18.2.1 Epidemiology
344(1)
18.2.2 Clinical features
345(1)
18.2.3 Cutaneous manifestations
345(1)
18.2.4 Psychiatric manifestations
346(1)
18.2.5 Management
347(1)
18.3 Rheumatoid Arthritis
348(13)
18.3.1 Epidemiology
348(1)
18.3.2 Etiopathogenesis
349(1)
18.3.3 Clinical features
349(1)
18.3.4 Cutaneous manifestations
349(2)
18.3.5 Psychiatric manifestations
351(2)
18.3.6 Laboratory findings
353(1)
18.3.7 Management
354(2)
18.3.8 Management of psychiatric issues
356(5)
19 Psychocutaneous manifestations of endocrine disorders
361(42)
Manmohan K. Kamboj
Ruqiya Shama Tareen
19.1 Introduction
361(1)
19.2 Diabetes Mellitus
361(6)
19.2.1 Clinical features
362(1)
19.2.2 Dermatological manifestations
363(2)
19.2.3 Psychiatric manifestations
365(1)
19.2.4 Management of psychiatric conditions
366(1)
19.3 Disorders of growth hormone
367(3)
19.3.1 Acromegaly
367(1)
19.3.2 Dermatological manifestations
367(1)
19.3.3 Psychiatric manifestations
368(1)
19.3.4 Diagnostic workup
369(1)
19.3.5 Clinical management
369(1)
19.3.6 Management of dermatological manifestations
370(1)
19.3.7 Management of psychiatric manifestations
370(1)
19.4 Thyroid hormone disorders
370(8)
19.4.1 Hypothyroidism
370(1)
19.4.2 Hyperthyroidism
371(1)
19.4.3 Clinical features of thyroid disorders
371(1)
19.4.4 Dermatological manifestations of hypothyroidism
372(1)
19.4.5 Dermatological manifestations of hyperthyroidism
373(1)
19.4.6 Psychiatric manifestations
373(2)
19.4.7 Diagnostic workup
375(1)
19.4.8 Management of hypothyroidism
375(1)
19.4.9 Management of hyperthyroidism
375(2)
19.4.10 Management of psychiatric disorders
377(1)
19.5 Adrenal gland disorders
378(6)
19.5.1 Hypoadrenocorticism (adrenal insufficiency [ Al] or Addison disease [ AD])
378(2)
19.5.2 Hyperadrenocorticism (Cushing syndrome)
380(4)
19.6 Disorders of parathyroid glands
384(6)
19.6.1 Hypoparathyroidism
384(4)
19.6.2 Hyperparathyroidism
388(2)
19.7 Disorders of hormones of the reproductive system
390(1)
19.8 Androgen disorders
390(4)
19.8.1 Hypogonadism in males
390(1)
19.8.2 Androgen disorders in Females
391(3)
19.9 Estrogen disorders
394(2)
19.9.1 Estrogen disorders in males
394(1)
19.9.2 Estrogen disorders in females
394(1)
19.9.3 Psychiatric manifestations of disorders of androgen and estrogens
395(1)
19.10 Conclusion
396(7)
20 Inborn errors of metabolism with psychiatric and dermatologic feature
403(18)
Manmohan K. Kamboj
Ruqiya Shama Tareen
20.1 Introduction
403(1)
20.2 Phenylketonuria [ PKU]
403(6)
20.2.1 Genetics and pathophysiology
404(1)
20.2.2 Clinical features
405(1)
20.2.3 Cutaneous manifestations
406(1)
20.2.4 Psychiatric manifestations
406(1)
20.2.5 Laboratory diagnosis
407(1)
20.2.6 Management
407(2)
20.3 Hartnup disease
409(1)
20.3.1 Genetics and pathophysiology
409(1)
20.3.2 Cutaneous manifestations
409(1)
20.3.3 Psychiatric manifestations
409(1)
20.3.4 Laboratory findings
410(1)
20.3.5 Management
410(1)
20.4 Homocystinuria
410(2)
20.4.1 Genetics and pathophysiology
410(1)
20.4.2 Clinical features
410(1)
20.4.3 Cutaneous manifestations
411(1)
20.4.4 Psychiatric Manifestations
411(1)
20.4.5 Management
412(1)
20.5 Porphyrias
412(4)
20.5.1 Genetics and prevalence
412(1)
20.5.2 Clinical features
413(1)
20.5.3 Cutaneous manifestations
413(1)
20.5.4 Psychiatric manifestations
414(1)
20.5.5 Laboratory diagnosis
415(1)
20.5.6 Management
415(1)
20.6 Conclusion
416(5)
Part VI SPECIAL ISSUES IN MANAGEMENT OF PSYCHOCUTANEOUS DISORDERS
421(80)
21 Psychiatric complications of dermatological treatments
423(10)
Joseph L. Calles
21.1 Introduction
423(1)
21.2 Epidemiology
423(1)
21.3 Clinical features by medication category
424(4)
21.3.1 Antibacterial agents
424(1)
21.3.2 Antiviral agents
425(1)
21.3.3 Corticosteroids
426(1)
21.3.4 Dapsone
426(1)
21.3.5 Antimalarial agents
426(1)
21.3.6 Retinoids
427(1)
21.3.7 Interferons
428(1)
21.3.8 Other agents
428(1)
21.4 Differential diagnosis
428(1)
21.5 Management
428(2)
21.5.1 Drug-drug interactions
429(1)
21.5.2 Non-pharmacologic interventions
429(1)
21.6 Conclusion
430(3)
22 Dermatologic manifestations of psychotropic medications
433(28)
Misha M. Heller
Meagan Barrett
Stefani Takahashi
Jenny Murase
Josephine L. Howard
22.1 Introduction
433(1)
22.1.1 Epidemiology
433(1)
22.2 Diagnosis
434(1)
22.3 Pathogenesis
435(1)
22.4 Categories
436(1)
22.5 Common adverse cutaneous reactions
436(17)
22.5.1 Pruritus
436(1)
22.5.2 Exanthematous eruptions
436(14)
22.5.3 Urticaria and angioedema
450(1)
22.5.4 Fixed drug eruptions
451(1)
22.5.5 Photosensitivity
451(1)
22.5.6 Pigmentation
452(1)
22.5.7 Diaphoresis
452(1)
22.5.8 Alopecia
452(1)
22.6 Serious and life-threatening cutaneous reactions
453(3)
22.6.1 Erythema multiforme
453(1)
22.6.2 Stevens-Johnson Syndrome and Toxic Epidermolysis Necrolysis
453(1)
22.6.3 Drug hypersensitivity syndrome
454(1)
22.6.4 Vasculitis
455(1)
22.6.5 Exfoliative dermatitis
455(1)
22.6.6 Anaphylactoid reactions
456(1)
22.7 General dermatologic conditions
456(2)
22.7.1 Acneiform eruptions
456(1)
22.7.2 Psoriasiform eruption
457(1)
22.7.3 Seborrheic eruption
457(1)
22.7.4 Lichenoid eruption
457(1)
22.8 Conclusion
458(3)
23 Non-pharmacological approaches to treat psychocutaneous disorders
461(10)
Philip D. Shenefelt
23.1 Introduction
461(1)
23.2 Non-pharmacological modalities
462(5)
23.2.1 Acupuncture
462(1)
23.2.2 Aromatherapy
462(1)
23.2.3 Biofeedback
463(1)
23.2.4 Brief dynamic psychotherapy
464(1)
23.2.5 Cognitive behavioral therapy methods
464(1)
23.2.6 Emotional freedom techniques (EFT)
464(1)
23.2.7 Eye Movement Desensitizing and Reprocessing (EMDR)
465(1)
23.2.8 Hypnosis
465(1)
23.2.9 Music
466(1)
23.2.10 Placebo
467(1)
23.2.11 Suggestion1
467(1)
23.3 Conclusion
467(4)
24 Psychiatric disorders frequently encountered in dermatology practices
471(30)
Ruqiya Shama Tareen
Anam Nisar Tareen
24.1 Introduction
471(1)
24.1.1 Epidemiology
472(1)
24.2 Mood disorders
472(5)
24.2.1 Epidemiology
472(3)
24.2.2 Diagnosis of depressive disorders
475(1)
24.2.3 Differential diagnosis of depressive disorders
476(1)
24.2.4 Management of depressive disorders
476(1)
24.3 Bipolar spectrum disorders
477(8)
24.3.1 Types of bipolar disorders
478(2)
24.3.2 Diagnosis of bipolar disorders
480(1)
24.3.3 Differential diagnosis of bipolar disorders
481(4)
24.4 Anxiety spectrum disorders
485(9)
24.4.1 Obsessive compulsive disorder
486(2)
24.4.2 Social anxiety disorder (SAD)
488(3)
24.4.3 Eating disorders
491(3)
24.5 Personality disorders (PDs)
494(4)
24.5.1 Introduction
494(1)
24.5.2 Clinical diagnosis
495(3)
24.6 Conclusion
498(3)
APPENDIX
501(18)
25 About the editors
503(4)
26 FDA approved psychotropic medication indications for children and adolescents
507(2)
27 Common psychiatric terms
509(4)
28 Common dermatotologic lesions
513(6)
Mohammad Jafferany
Index 519(8)
Plate section 527
Ruqiya Shama Tareen, Donald E. Greydanus, Mohammad Jafferany, and Dilip R. Patel, Michigan State University, East Lansing, Michigan, USA; Joav Merrick, Ministry of Social Affairs and Social Services, Jerusalem, Israel.